Nialamide was one of the first MAOI (monoamine oxidase inhibitor) antidepressants. It is chemically related to iproniazide, another MAOI derived from isonicotinic acid.

Uses

---

Approved

Nialamide is effective for depression characterized by anergia symptoms, endogenous depression, and reactive depression.

Unapproved/Off-Label/Investigational

Nialamide is sometimes used in the treatment of trigeminal neuralgia. It has also been studied for alcoholism, dermatomally distributed vitiligo, irregular menstrual cycle,, angina, cerebrovascular disorders, and the prevention of streptomycin-induced deafness.

Side effects

---

Side effects of nialamide include insomnia, vertigo, hyperhidrosis, weight gain, vomiting, tachycardia, constipation, dry mouth, upset stomach, orthostatic hypotension and decreased systolic pressure.

Tradenames

---

Nialamide is sold under Psicodisten®, Niaquitil®, Nialamid®, Niamidal®, Niamide®, Novazid®, Nuredal®, Niamid® (Italy, Belgium, Netherlands, England, United States), Niazin®, Nyazin®, Surgex® (Italy), Mygal®, Delmoneurina®, Isalizina® (Italy), Espril® (Italy), and Nyezin®.

References and End Notes

---

2. abstract PMID 5321917 List of Print Collections
3. in French New York Academy of Medicine Library holding
4. List of Library Holdings
5. in French PMID 13841128 Harvard University Library Holding
6. in French PMID 5930244 List of Library Holdings
7. in Russian PMID 1647635 List of Library Holdings
8. List of Library Holdings
9. List of Library Holdings
10. in Russian No absract. PMID 1021625 List of Library Holdings
11. in Russian PMID 1218262 List of Library Holdings
12. No abstract. PMID 4467804 List of Library Holdings
14. see BIAM, 2001.
15. see BIAM, 2001.
16. see BIAM, 2001.
17. National Center for Biotechnology Information.

Monoamine oxidase inhibitors

Ниаламид